Assessment of Bone Micro-Architecture Using HR-pQCT



Status:Completed
Conditions:Osteoporosis
Therapuetic Areas:Rheumatology
Healthy:No
Age Range:50 - 85
Updated:5/27/2013
Start Date:April 2012
End Date:July 2013
Contact:Melissa Guan
Email:melissa.guan@ucsf.edu
Phone:415-353-4216

Use our guide to learn which trials are right for you!

Non-Invasive Assessment of Bone Micro-architecture and Strength Changes in Men With Osteopenia and Osteoporosis


In the context of male osteoporosis, we hypothesize that regional changes in trabecular
bone, as well as changes in cortical porosity will play a major role, and thus also affect
bone strength. In developing therapeutics the response of individual compartments, regional
variations post-therapy will have considerable impact on selecting the therapies as well as
monitoring response to therapy. This study, a precursor to other therapeutic trials, will
lay the ground-work for the future.


We will recruit 80 subjects who will be stratified into groups based on their T-scores. All
subjects will be imaged at Baseline and 12 months. Measures of bone micro-architecture in
the tibia and radius using peripheral computed tomography, bone strength measures through
finite element analysis will be obtained at all time points. DXA measures at the spine,
femur and forearm will be obtained as reference measures. In addition whole body DXA scans
will be performed for assessment of body composition.

Inclusion Criteria:

1. Men 50-85 years old

2. Patients must be willing to undergo a DXA scan.

3. Patients should be willing to undergo HRpQCT scan of the radius and tibia.

Exclusion Criteria:

1. Inability to tolerate CT scans

2. Use of medications known to impact bone and mineral metabolism:

- use of a bisphosphonate or teriparatide in the last year or for >12 months ever;

- current calcitonin;

- prednisone >5 mg daily or the equivalent glucocorticoid for >10 days in the last
3 months;

- current testosterone therapy;

- current thiazolidinedione (TZD);

- current androgen deprivation therapy;

- current use of an antiepileptic agent that alters hepatic vitamin D clearance;

- use of thyroid hormone replacement with current thyroid stimulating hormone <0.1
mIU/L

3. Disease known to affect bone (e.g., primary hyperparathyroidism, Pagets disease,
clinically significant liver disease)

4. Illicit drug use or alcohol use >3 drinks/day

5. Serum calcium >10.2 mg/dL or calculated creatinine clearance <30 mL/min

6. Weight >350 pounds (the maximum weight limit of the DXA)

7. Hardware in the lumbar spine

8. History of bilateral hip replacement, or bilateral wrist or ankle fracture
We found this trial at
1
site
San Francisco, California 94107
?
mi
from
San Francisco, CA
Click here to add this to my saved trials